Calamos Advisors LLC Sells 36,137 Shares of CareDx, Inc (NASDAQ:CDNA)

Calamos Advisors LLC lessened its holdings in CareDx, Inc (NASDAQ:CDNA) by 29.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 87,265 shares of the company’s stock after selling 36,137 shares during the period. Calamos Advisors LLC owned approximately 0.16% of CareDx worth $1,868,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Exchange Traded Concepts LLC increased its holdings in shares of CareDx by 6.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 29,107 shares of the company’s stock worth $623,000 after buying an additional 1,816 shares during the last quarter. SG Americas Securities LLC grew its position in CareDx by 31.0% in the fourth quarter. SG Americas Securities LLC now owns 24,087 shares of the company’s stock worth $516,000 after acquiring an additional 5,706 shares in the last quarter. ARS Investment Partners LLC increased its stake in CareDx by 6.3% during the fourth quarter. ARS Investment Partners LLC now owns 101,968 shares of the company’s stock worth $2,183,000 after acquiring an additional 6,083 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in CareDx during the third quarter valued at approximately $557,000. Finally, Lord Abbett & CO. LLC bought a new stake in shares of CareDx in the 3rd quarter valued at approximately $10,873,000.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. HC Wainwright reissued a “neutral” rating and set a $26.00 target price on shares of CareDx in a research report on Tuesday, January 14th. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. Wells Fargo & Company upgraded shares of CareDx from an “underweight” rating to an “equal weight” rating and lowered their target price for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. BTIG Research cut their price target on shares of CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, November 5th. Finally, The Goldman Sachs Group raised their price objective on shares of CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.33.

Insiders Place Their Bets

In other news, Director Peter Maag sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the director now owns 330,024 shares in the company, valued at approximately $8,250,600. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.90% of the company’s stock.

CareDx Price Performance

Shares of CDNA opened at $23.10 on Wednesday. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -8.56 and a beta of 1.87. The company has a 50-day moving average of $22.91 and a 200 day moving average of $25.14. CareDx, Inc has a 1-year low of $7.42 and a 1-year high of $34.84.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The firm had revenue of $82.88 million during the quarter, compared to analyst estimates of $80.04 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. CareDx’s quarterly revenue was up 23.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.43) earnings per share. On average, equities analysts anticipate that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.